Baldacci Simon, Grégoire Valérie, Patrucco Enrico, Chiarle Roberto, Jamme Philippe, Wasielewski Eric, Descarpentries Clotilde, Copin Marie-Christine, Awad Mark M, Cortot Alexis B
Univ Lille, Department of Thoracic Oncology, CHU Lille, F-59000, Lille, France.
Univ Lille, Department of Pathology, CHU Lille, F-59000, Lille, France.
Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 May 27.
Immune checkpoint inhibitors (ICI) have become a major treatment in advanced non small cell lung cancer (NSCLC). However, some patients do not benefit from ICI, especially those harboring an ALK rearrangement. Here, we report a case of prolonged complete tumor response to immunotherapy in an ALK-rearranged NSCLC patient.
We verify ALK expression and rearrangement on formalin-fixed paraffin-embedded tumor samples of the patient by Immunohistochemistry and Fluorescence In Situ Hybridization analysis. The patient provided written informed consent authorizing publication of clinical case.
We report the case of 48 years old man with a ALK-rearranged NSCLC. This patient displayed a complete response for 16 months under nivolumab therapy in third line setting after ceritinib and platin based chemotherapy.
This is the first case of complete and prolonged response to ICI in ALK rearranged NSCLC. This case supports the idea that some ALK rearranged NSCLC could durably benefit from immunotherapy.
免疫检查点抑制剂（ICI）已成为晚期非小细胞肺癌（NSCLC）的主要治疗方法。然而，一些患者无法从ICI中获益，尤其是那些存在ALK重排的患者。在此，我们报告一例ALK重排的NSCLC患者对免疫治疗产生长期完全肿瘤缓解的病例。
我们通过免疫组织化学和荧光原位杂交分析，在患者福尔马林固定石蜡包埋的肿瘤样本上验证ALK表达和重排情况。患者提供了书面知情同意书，授权发表该临床病例。
我们报告一例48岁ALK重排的NSCLC男性患者。该患者在接受色瑞替尼和铂类化疗后的三线治疗中，接受纳武单抗治疗后出现了16个月的完全缓解。
这是首例ALK重排的NSCLC对ICI产生完全且持久缓解的病例。该病例支持了一些ALK重排的NSCLC可能从免疫治疗中持久获益的观点。
